Post-Operative Pain Therapeutics Pipeline to Witness Many Technological Advancements in the Coming Years     |    Global Coding and Marking Market Witness 9.4% CAGR During 2017 – 2023     |    Global HIV Diagnosis Market to Witness 10.6% CAGR during 2017 – 2023
P&S Market Research - A market research firm

Immunotherapy Drugs Market

P&S Market Research-Immunotherapy Drugs Market report

Global Immunotherapy Drugs Market Size, Share, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS11095
Available Format: pdf

Market Overview

Immunotherapy drugs refer to the drugs that enhance, suppress or stimulate the body’s immune system and modulate the immune responses of the body. Immunotherapy drugs improve the immune system of the body, restrict the growth of the diseases, and enhance the immunity to fight against the diseases.  These drugs are used in cancer treatment to restrict the growth of cancer cell and prevent it from growing to the other parts of the body. Immunotherapy drugs are an effective treatment for autoimmune diseases, immunodeficiency, inflammatory diseases, and biological infectious diseases. The development and launch of new immunotherapy drugs such as elotuzumab, zanolimumab, onartuzumab into the market is expected spur the growth of the global immunotherapy drugs market during the forecast period.

On the basis of therapy area, cancer is expected to hold the largest share in the global immunotherapy drugs market during the forecast period. Emergence of immunotherapy as a first line of treatment in cancer and significant rise in prevalence of cancer are some of the factors driving the growth of the immunotherapy drugs market for cancer.

Based on type of drugs, monoclonal antibodies held largest share largest of the global immunotherapy drugs market, in 2016. The growth of the segment is mainly driven by rising demand for personalized medicine and development of new drugs.  Hospitals are the major end-users for the immunotherapy drugs due to the presence of major volume of patients in the hospital.

Market Dynamics

Growth Drivers

Global immunotherapy drugs market is expected to grow significantly during the forecast period. The major factors driving growth of the market are increasing adoption of targeted therapy over traditional therapy, rising demand for monoclonal antibodies, fast track and orphan drug designations, increasing prevalence of lifestyle diseases, and emergence of biosimilars. Targeted therapy is a new treatment process for cancer, which involves identifying and attacking cancer cells using drugs. The increasing adoption of targeted therapy over traditional therapy is due to its characteristic of attacking the defective proteins and restricting the growth of cancer cells. Moreover, drugs like monoclonal antibodies, that can be customized according to the treatment of the patient, are significant in treating diseases. These properties of targeted therapy and monoclonal antibodies are positively impacting the market, thereby driving the growth of the global immunotherapy drugs market.

Moreover, the prevalence of lifestyle diseases is increasing significantly. According to the Centers for Disease Control and Prevention (CDC), 614,348 people died from heart diseases in 2015, in the U.S. According to the World Health Organization (WHO), approximately 17.7 million people died from CVDs in 2015, representing 31.0% of all global deaths. Of these deaths, an approximate of 7.4 million deaths were due to coronary heart disease and 6.7 million were due to stroke. Therefore, increasing prevalence of lifestyle diseases has a positive impact on the growth of the global immunotherapy drugs market.


High cost of immunotherapy treatment, and increased attrition rate in the product development cycle act as major barriers in the growth of the global immunotherapy drugs market. Additionally, lack of awareness of biologic cancer therapy is expected to hamper the growth of the global market to an extent.

Opportunities and Trends

The key trend witnessed in the global immunotherapy drugs market is the gradual shift from chemotherapy to immunotherapy in cancer treatment. Immunotherapy drugs are customized according to the treatment for the patient and also provide better immunity and treatment for the diseases. Additionally, the improving healthcare in emerging economies is creating ample opportunities for the growth of the global immunotherapy drugs market. In emerging economies such as India, China, Brazil, and Mexico, government is increasingly spending on the healthcare. According to World Bank, Brazil spent 8.3% of the total $2.456 trillion GDP on healthcare, in 2014. Similarly, China spent 5.5% of its GDP on healthcare, whereas, Mexico spent 6.3% of GDP on healthcare, in 2014. It is an opportunity for the key players to introduce new and innovative drugs in these emerging markets, which is likely to further prompt the end users to adapt the new immunotherapy drugs.

Insights by Geography

Geographically, North America was the largest market for immunotherapy drugs in 2016. Some of the key factors driving the growth of the immunotherapy drugs market in North America include, rising prevalence of cancer, presence of the established players in the region, increasing research and development investments and high healthcare expenditures. Private health insurance plays an important role in U.S. healthcare system, and provides primary healthcare coverage to large population group leading to affordability of better healthcare facilities.  Asia-Pacific is expected to be the fastest growing market for immunotherapy drugs due to the admissible regulatory scenario, availability of skilled labor, and low manufacturing cost for drugs as compared to the developed markets.

Competitive Landscape

Some of the key players in the global immunotherapy drugs market are AstraZeneca plc, Eli Lilly and Company, Bristol-Myers Squibb, Amgen, Inc., GlaxoSmithKline, F. Hoffmann-La Roche AG, AbbVie, Inc., Merck & Co., Inc., Novartis International AG, and Johnson & Johnson.

With respect to strategic developments, various new product launches and strategic alliances have been taking place in the patient positioning equipment market.

In January 2017, AbbVie, Inc. received FDA approval for IMBRUVICA, used to treat patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) and require systemic therapy, and has received at least one prior anti-CD20-based therapy.

By Therapy Area

  • Cancer
    • Solid Tumor
    • Malignant
  • Autoimmune & Inflammatory Diseases
  • Infectious Diseases
  • Others

By Type of Drug

  • Monoclonal Antibodies
  • Adult Vaccines
    • Preventive Vaccines
    • Therapeutic Vaccines
  • Checkpoint Inhibitors
  • Interferons Alpha & Beta
  • Interleukins
  • Others

By End User

  • Hospitals
  • Clinics
  • Others

Geographical Segmentation

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (MEA)

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

Group License

Group License authorizes access of the publication upto 5 users.

Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.


Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment